No-Spa Forte (Drotaverine Hydrochloride)

Drotaverine Hydrochloride, the active ingredient in No-Spa Forte, is a phosphodiesterase inhibitor presented as a tablet for oral use. It relaxes smooth muscle and is employed to relieve abdominal, renal, biliary and menstrual cramp pain, and is indicated for adult patients experiencing smooth muscle spasm associated with gastrointestinal, urinary or gynecological conditions.

GNH USA supplies No-Spa Forte as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution.

Drotaverine Hydrochloride is an antispasmodic that acts on smooth muscle spasm conditions. - Abdominal pain: provides relief by relaxing gastrointestinal smooth muscle. - Renal colic: reduces ureteral spasm to alleviate kidney stone pain. - Biliary colic: eases gallbladder muscle contraction, decreasing pain. - Menstrual cramps: diminishes uterine smooth muscle contractions, improving dysmenorrhea. - Irritable bowel syndrome spasm: helps reduce abdominal discomfort associated with IBS. - Postoperative ileus: may facilitate return of bowel motility by reducing spasm.

Drotaverine Hydrochloride may cause a range of adverse reactions, varying from mild to serious. Common Side Effects: - Nausea: mild gastrointestinal upset. - Dizziness: transient light‑headedness. - Dry mouth: reduced salivation. Serious or Rare Side Effects: - Allergic reactions: rash, itching, swelling, or anaphylaxis. - Severe hypotension: marked blood pressure fall requiring medical attention. - Hepatic dysfunction: elevated liver enzymes or hepatitis.

When prescribing Drotaverine Hydrochloride, clinicians should consider several precautionary measures to ensure patient safety. - Assess renal function: adjust use in patients with severe renal impairment. - Monitor blood pressure: watch for hypotensive episodes, especially in the elderly. - Use caution in hepatic disease: consider liver function before initiating therapy. - Avoid in known hypersensitivity: discontinue if allergic reactions occur. - Review concomitant medications: evaluate for potential drug interactions. - Store at ambient temperature: keep in the original pack, protect from moisture.

Drotaverine Hydrochloride can interact with other medicines; awareness of major and moderate interactions helps prevent adverse outcomes. Major Interactions (Avoid): - Potent CYP3A4 inhibitors: may increase drotaverine plasma levels. - Other antispasmodics: additive smooth‑muscle relaxation can cause excessive hypotension. - Antihypertensive agents: combined effect may lead to clinically significant blood pressure drop. Moderate Interactions (Monitor Closely): - Other phosphodiesterase inhibitors: monitor for enhanced vasodilatory effects. - MAO inhibitors: observe for possible cardiovascular changes. - QT‑prolonging drugs: watch for additive risk of arrhythmia.